as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹417.0
Change
+6.55 (1.6%)
Open
₹411.0
Prev. Close
₹410.45
Day High
₹422.1
Day Low
₹410.45
Volume Analysis
Traded
159,525
Delivered
79,495
Delivery %
49.83%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (46.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹434.24 | ₹428.17 | ₹422.59 | ₹416.52 | ₹410.94 | ₹404.87 | ₹399.29 |
| Fibonacci | ₹428.17 | ₹423.72 | ₹420.97 | ₹416.52 | ₹412.07 | ₹409.32 | ₹404.87 |
| Camarilla | ₹420.2 | ₹419.14 | ₹418.07 | ₹416.52 | ₹415.93 | ₹414.86 | ₹413.8 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-5.35%
1 Week
+0.8%
1 Month
+1.45%
3 Months
+4.91%
6 Months
+68.81%
1 Year
+4.29%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Company Overview
Sector
Healthcare
Market Cap
₹5,442 Cr
P/E (TTM)
112.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Gujarat Themis Biosyn Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 56/100. The strongest factor is Business Quality (100/100), while Valuation (1/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (46.0%); promoter holding is falling. FII holding has been rising.
TopFund Score — Fundamentals Quality
56/100 — AverageData confidence: 66/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Valuation
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Promoter holding has decreased over last quarter: -11.5%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Trading window closes from 1 Oct 2026; Q2 FY27 results board meeting date pending.
Please refer to the Newspaper Publication of Corrigendum to the Notice of 45th Annual General Meeting.
Record date fixed on September 23, 2026 for FY2025-26 final dividend, subject to AGM approval.
GTBL completed acquisition of Japan's MBJ on Sept 18, 2026; invested ₹475 crore equity, ₹745 crore loan.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Sales + | 36 | 44 | 44 |
| Expenses + | 22 | 25 | 23 |
| Operating Profit | 14 | 19 | 21 |
| OPM % | 39.0% | 44.0% | 48.0% |
| Other Income + | 0 | 1 | 0 |
| Interest | 0 | 2 | 2 |
| Depreciation | 2 | 4 | 4 |
| Profit before tax | 12 | 14 | 15 |
| Tax % | 25.0% | 24.0% | 27.0% |
| Net Profit + | 9 | 11 | 11 |
| EPS in Rs | 1 | 1 | 1 |
| Raw PDF | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2026 | |
|---|---|
| Sales + | 166 |
| Expenses + | 90 |
| Operating Profit | 76 |
| OPM % | 46.0% |
| Other Income + | 2 |
| Interest | 3 |
| Depreciation | 13 |
| Profit before tax | 62 |
| Tax % | 25.0% |
| Net Profit + | 47 |
| EPS in Rs | 4 |
| Dividend Payout % | 0.0% |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2026 | |
|---|---|
| Reserves | — |
| Borrowings + | — |
| Other Liabilities + | — |
| Total Liabilities | — |
| Fixed Assets + | — |
| CWIP | — |
| Investments | — |
| Other Assets + | — |
| Total Assets | — |
| Equity Capital | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2026 | |
|---|---|
| Cash from Operating Activity + | — |
| Cash from Investing Activity + | — |
| Cash from Financing Activity + | — |
| Net Cash Flow | — |
| CFO/OP | — |
| Free Cash Flow | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 28.23% | 27.26% | 26.52% | 26.47% | 26.55% | 26.05% | 25.44% | 25.01% | 26.0% | 26.15% | 26.18% | 21.95% |
| Promoters | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.86% | 70.87% | 59.33% |
| FII | 0.86% | 1.05% | 1.44% | 1.49% | 1.42% | 1.91% | 2.51% | 2.95% | 1.96% | 1.8% | 1.76% | 4.93% |
| DII | 0.04% | 0.82% | 1.18% | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 13.79% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Gujarat Themis Biosyn Ltd (this stock) | 5,442 | 112.0 | — | — |
| Fdc Limited | 5,641 | 18.3 | 2.26 | 11.2% |
| Rpg Life Sciences Ltd | 5,045 | 43.2 | 8.34 | 19.3% |
| Artemis Med Service Ltd | 5,917 | 51.0 | 6.34 | 12.0% |
| Iol Chem And Pharma Ltd | 5,965 | 33.8 | 3.31 | 8.41% |
| Senores Pharmaceuticals L | 6,241 | 49.4 | 6.67 | 13.4% |
| Zota Health Care Limited | 4,629 | — | 6.69 | -15.0% |
Which Mutual Funds Hold Gujarat Themis Biosyn Ltd?
Frequently Asked Questions about Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Ltd (GUJTHEM) closed at ₹417.0 on NSE on 25 September 2026, up 6.55 (1.6%) from the previous close.
Gujarat Themis Biosyn Ltd trades on the NSE (National Stock Exchange of India) under the symbol GUJTHEM.
Gujarat Themis Biosyn Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 112.0.
Gujarat Themis Biosyn Ltd has a dividend yield of 0.16%.
Gujarat Themis Biosyn Ltd's 52-week high is ₹479.0 and its 52-week low is ₹225.0.
Gujarat Themis Biosyn Ltd has a market capitalisation of ₹5,442 crore.
Gujarat Themis Biosyn Ltd has a TopFund Quality Score of 56/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Gujarat Themis Biosyn Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.